Posted by Michael Wonder on 24 Jan 2020
FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer
23 January 2020 - Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Epithelioid sarcoma is a rare sub-type of soft tissue sarcoma that often occurs in young adults.
Tazverik’s approval was based on the results of a clinical trial enrolling 62 patients with metastatic or locally advanced epithelioid sarcoma.
